49 results
Keyword Oncaspar Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Oncaspar (updated)
pegaspargase, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 14/01/2016, Revision: 16, Authorised, Last updated: 25/01/2023Oncaspar Cancer Neoplasms Leukemia … Oncaspar … Assessment report Oncaspar International non-proprietary … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 November 2015
Last updated: 20/11/2015Oncaspar … -
List item
National expert: Marie-Christine Annequin, National Agency For The Safety Of Medicine And Health Products (updated)
- Declaration of interests - 79.83 KB | PDF
- Curriculum Vitae - 18.28 KB | PDF
SEQIRUS...), Biotech (UNITUXIN, GAZYVARO, ONCASPAR, REKOVELLE, AIMOVIG, PEGVALIASE, BEVECTRA … -
List item
National expert: Leo Lambart, National Agency For The Safety Of Medicine And Health Products (updated)
- Declaration of interests - 80.47 KB | PDF
- Curriculum Vitae - 17.57 KB | PDF
Writing of PSUR/ DSUR/ PADER of Oncaspar and Onivyde - Signal detection … -
List item
National expert: Honar Cherif, European Medicines Agency (updated)
- Declaration of interests - 82.23 KB | PDF
- Curriculum Vitae - 23.8 KB | PDF
thrombcytopenia 03/2022-03/2022 Servier Oncaspar (one Advisory Boars participation) Acute … -
List item
Human medicine European public assessment report (EPAR): Tecartus (updated)
Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel), Lymphoma, Mantle-Cell
Date of authorisation: 14/12/2020,
, 
, 
, Revision: 4, Authorised, Last updated: 30/01/2023
-
List item
Human medicine European public assessment report (EPAR): Spectrila
asparaginase, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 14/01/2016, Revision: 5, Authorised, Last updated: 09/10/2020 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 02/02/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 February 2021
European Medicines Agency, Amsterdam, the Netherlands, from 22/02/2021 to 25/02/2021, Last updated: 07/12/2021 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 27/01/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 February 2021
European Medicines Agency, Amsterdam, the Netherlands, from 08/02/2021 to 11/02/2021, Last updated: 08/02/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 May 2022
European Medicines Agency, Amsterdam, the Netherlands, from 16/05/2022 to 19/05/2022, Last updated: 12/08/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2022 to 24/03/2022, Last updated: 12/08/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 September-1 October 2020
Virtual meeting, from 28/09/2020 to 01/10/2020, Last updated: 29/09/2020 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 June 2022
European Medicines Agency, Amsterdam, the Netherlands, from 20/06/2022 to 23/06/2022, Last updated: 18/08/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 14-17 May 2018
European Medicines Agency, London, UK, from 14/05/2018 to 17/05/2018, Last updated: 14/05/2018 -
List item
Parallel distribution: Regulatory and procedural guidance
Last updated: 09/06/2021 -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 October 2020
Virtual meeting, from 12/10/2020 to 15/10/2020, Last updated: 16/10/2020 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 September 2018
European Medicines Agency, London, UK, from 03/09/2018 to 06/09/2018, Last updated: 13/03/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 September 2018
European Medicines Agency, London, UK, from 17/09/2018 to 20/09/2018, Last updated: 31/10/2018 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 April 2021
European Medicines Agency, Amsterdam, the Netherlands, from 19/04/2021 to 22/04/2021, Last updated: 07/12/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 February 2018
European Medicines Agency, London, UK, from 05/02/2018 to 08/02/2018, Last updated: 13/03/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 November 2015
European Medicines Agency, London, UK, from 16/11/2015 to 19/11/2015, Last updated: 16/11/201511 3.1.6. Oncaspar - pegaspargase - EMEA/H/C/003789 … -
List item
Committee for Medicinal Products for Human Use (CHMP): 24-27 January 2022
European Medicines Agency, Amsterdam, the Netherlands, from 24/01/2022 to 27/01/2022, Last updated: 16/03/2022